🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,067 results for “Hospital” Clear

  1. PIK3CA inhibitor

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Neoplasm

    phase 2 small molecule active

    1 trial

  2. PLD and Carboplatin

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. PM8002

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  4. Paclitaxel Polymeric Micelles for Injection and Cisplatin combined with Cadonilimab

    The First People's Hospital of Lianyungang

    Locally Advanced Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  5. Pancreatoduodenectomy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 2 other active

    1 trial

  6. Pectin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Slow Transit Constipation

    phase 2 small molecule active

    1 trial

  7. Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen

    The First People's Hospital of Lianyungang

    NK-T-Cell Lymphoma, Extranodal

    phase 2 small molecule active

    1 trial

  8. Pemazyre 4.5 mg tablets

    Ningbo Cancer Hospital

    Recurrent or metastatic solid cancer harboring a FGFR1,2 ,3 fusion/rearrangement or activating mutation, outside of the approved indications for any selective FGFR inhibitor in France

    phase 2 small molecule active

    1 trial

  9. Pembrolizumab 200 mg IV infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stage IIIB(N2) Non-small Cell Lung Cancer

    phase 2 mab active

    1 trial

  10. Pembrolizumab Injection

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  11. Pemebit

    Hospital Authority, Hong Kong

    Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  12. Pemetrexe

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Central Nervous System Tumors

    phase 2 small molecule active

    1 trial

  13. Pemetrexed

    The First People's Hospital of Lianyungang

    Colorectal Neoplasms

    phase 2 small molecule active

    1 trial

  14. Pemetrexed

    The First People's Hospital of Lianyungang

    Leptomeningeal Metastasis

    phase 2 small molecule active

    2 trials

  15. Pemetrexed (1)

    The First People's Hospital of Lianyungang

    Leptomeningeal Metastases

    phase 2 small molecule completed

    1 trial

  16. Pirarubicin

    The First People's Hospital of Lianyungang

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  17. Placebo

    Hospital Authority, Hong Kong

    STOMACH NEOPLASM

    phase 2 small molecule active

    1 trial

  18. Plerixafor

    The First People's Hospital of Lianyungang

    Relapsed Adult ALL

    phase 2 small molecule active

    1 trial

  19. Pluvicto 1 000 MBq/mL solution for injection/infusion

    Ningbo Cancer Hospital

    Clear Cell Renal Cell Carcinoma (ccRCC)

    phase 2 small molecule active

    1 trial

  20. Postoperative adjuvant lenvatinib

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  21. Pre-operative chemotherapy

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  22. Precision Cells

    Ningbo Cancer Hospital

    Precision Cell Immunotherapy

    phase 2 mab active

    1 trial

  23. Prednisone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Langerhans Cell Histiocytosis of Bone

    phase 2 small molecule active

    1 trial

  24. Prednisone

    Nanjing Children's Hospital

    Henoch-Schoenlein Purpura Nephritis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources